Navigation Links
Medicago named in Presidential report on meeting the challenges of pandemic influenza
Date:8/31/2010

QUEBEC CITY, Aug. 31 /PRNewswire-FirstCall/ - Medicago Inc. (TSX: MDG), a clinical-stage biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it was included in a report of President Obama's Council of Advisors on Science and Technology entitled "Report to the President on Reengineering the Influenza Vaccine Production Enterprise to Meet the Challenges of Pandemic Influenza", which was released earlier this month. U.S. Health and Human Services Secretary Kathleen Sebelius and other public health officials held a briefing to discuss this report and the $2 billion plan to accelerate the development of drugs and vaccines to prevent the spread of infectious diseases.

The report examined the importance to the U.S.A. of more rapidly and reliably producing effective vaccines, at a sufficient scale to protect all U.S. residents, in response to the emergence of pandemic influenza. The report stated, "Protecting the nation from an influenza pandemic...requires tightening the schedule for making vaccine substantially: in a serious pandemic, saving weeks could translate into saving tens of thousands of lives." Medicago was notably mentioned as an example of a recombinant influenza vaccine technology in clinical development.

"We are thrilled to be identified by the President's top scientific advisors as advancing the development of a recombinant vaccine technology that offers speed and cost advantages over the current method," said Andy Sheldon, President and CEO of Medicago.

The U.S. government's new initiative supports the development, clinical testing, and approval of influenza vaccines made using recombinant DNA technology. The investment strategy allows for flexibility in financing of promising vaccine production platforms, and creates downstream incentives for products that meet the target product profile and producti
'/>"/>

SOURCE Medicago Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Medicago reports positive Phase I results for its avian flu pandemic vaccine
2. Medicago to present at the U.S. Department of Health and Human Services Global Health Security Initiative Workshop
3. Medicago awarded contract by the U.S. Army to explore applications of its plant-based technology in renewable energy
4. Medicago begins human clinical testing with its avian flu pandemic vaccine
5. Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine
6. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
7. Medicago succesfully expresses VLP antigen for A H1N1 strain
8. Medicago initiates work on Swine Flu strain
9. maxIT Healthcare Named to Inc. 5000 List
10. BioPharm Systems Named to the 2010 Inc. 500
11. 5000 List of Fastest-Growing Companies in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... licensed to biotechnology firms has revealed early bottlenecks ... roadblocks, the researchers suggest that better communication of ... lead to faster commercialization down the road. , ... in university laboratories and licensed to biotechnology firms. ... have a high failure rate. But a new ...
(Date:8/20/2014)... American Indians largely were wiped out by diseases such ... to the New World by European explorers., One report ... in the Americas shortly before Europeans arrived, and roughly ... But new research led by anthropological geneticists Anne Stone ... University of Tubingen in Germany indicates the diagnosis of ...
(Date:8/20/2014)... the first time, chemists have succeeded in measuring vibrational ... resolution. The study reveals how vibration of a single ... , The study was performed at the University ... the University of Jyvskyl works as a visiting fellow ... the study. The second team was lead by Professor ...
(Date:8/20/2014)... Fla. , Aug. 20, 2014 ... will host a conference call to provide an ... 2014Time:4:30 p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 (U.S. ... 9126599 Live web cast: www.neurotropebioscience.com , under "Investor ... hours after completion through September 2, 2014 at ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3Seeing a molecule breathe 2Neurotrope To Host Conference Call 2
... season on CEOs lately but when luminaries like management god ... something real and serious is taking place. Heres what Herr ... January 12, 2004 issue of Fortune Magazine, the compensation inflation ... of the management team. In an executive program I have ...
... Wis. The recent onslaught of e-mail viruses, overabundant ... for computer user protection. In light of this, ... Wisconsin companies, recently began offering new computer security technologies ... spam cost U.S. corporations $8.9 billion dollars in 2002 ...
... DEMO 2004 reaches its final week, I promised I'd share ... not just at DEMO, but in the week ahead. , ... it feels a lot like the enterprise market some 20 ... departments in the early 80s) is acutely focused on the ...
Cached Biology Technology:The CEO Crisis 2Wisconsin Telcos Offer New Internet Security Solutions 2The Enterprise and the Individual 2The Enterprise and the Individual 3
(Date:8/20/2014)... of Tennessee, Knoxville, research finds life can persist in ... was part of a team that examined waters and ... ice sheet and found the extreme environment supports microbial ... Jill Mikucki and her colleagues has implications for life ... the solar system. The findings are published in the ...
(Date:8/20/2014)... Issue Serious allergic reactions to food often ... some children.    What you should know ... and this number may be increasing, especially among children. Up ... food allergies.  The symptoms of allergic reactions ... difficulties and loss of consciousness. Symptoms can also develop at ...
(Date:8/20/2014)... Scientists from the University of Tbingen, Arizona State University, ... and Public Health Institute (Swiss TPH) isolated Mycobacterium ... at least 1000 years old. The pathogen is a ... only occasionally causes disease in humans today. These researchers ... the Peruvian coast. "The link to sea lions was ...
Breaking Biology News(10 mins):University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3
... and going to work is hard enough every day. But ... of your job down the smallest detail and the ... of credentials might mean starting from scratch. These are the ... make U.S. homes more energy efficient. A recent collaboration ...
... called ADAP (adhesion and degranulation-promoting adaptor protein) is able ... new University of Cambridge research reveals. The researchers, who ... discovery will lead to new ways of combatting HIV. ... who led the research, said: "One exciting aspect about ...
... Oct. 1, 2013  Pfenex Inc. today announced that the ... Biomedical Advanced Research and Development Authority (BARDA), has modified ... with the existing Pfenex contractual relationship begun in July, ... funding to support the development of a next generation ...
Cached Biology News:Weatherization work guidelines launched 2Weatherization work guidelines launched 3Weatherization work guidelines launched 4Weatherization work guidelines launched 5Weatherization work guidelines launched 6New target to fight HIV infection identified 2Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract and Increase Funding for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine 2
Goat polyclonal to STMN2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: AKTAMAYKEK, corresponding to C terminal amino acids 2-11 of STMN2. Entrez Gene ID: 11075 Swi...
Mouse monoclonal antibody to PAEP - progestagen-associated endometrial protein (placental protein 14, pregnancy-associated endometrial alpha-2-globulin, alpha uterine protein)...
Mouse polyclonal antibody to MCFD2 - multiple coagulation factor deficiency 2...
Volume adapter mounts on top of the 96 well FiltrEX filter plate and allows larger volumes (1mL) to be applied to each well in a filter plate. Adapters are nonsterile....
Biology Products: